TMCnet News

Research and Markets: Rhabdomyosarcoma - Active Pharmaceutical Ingredients Insights 2015-2016
[July 01, 2015]

Research and Markets: Rhabdomyosarcoma - Active Pharmaceutical Ingredients Insights 2015-2016


Research and Markets (http://www.researchandmarkets.com/research/9rck8m/rhabdomyosarcomaa) has announced the addition of the "Rhabdomyosarcoma-API Insights" report to their offering.

Rhabdomyosarcoma-API Insights, 2015 report provides Rhabdomyosarcoma drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Rhabdomyosarcoma. The Report provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent, patent exclusivity information and competitive landscape. The research analysis also presents the global sales forecasts data for the Rhabdomyosarcoma drugs till 2016.

The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.



India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA (News - Alert) have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China.

Scope


- A snapshot of the global Market therapeutics scenario for Secondary Adrenal Insufficiency.

- A review of the marketed products under prescription for Secondary Adrenal Insufficiency, regulatory information and marketing status.

- Coverage of global patent coverage and detailed commentaries on the US patent challenges.

- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.

- Product profiles for marketed products for Secondary Adrenal Insufficiency with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.

- Coverage of API Manufacturers for Secondary Adrenal Insufficiency drugs in the United States, Europe and Asian Regions with location details.

- Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Secondary Adrenal Insufficiency drugs.

- Key discontinued Marketed products.

- Global Sales Figure from 2012-2016.

For more information visit http://www.researchandmarkets.com/research/9rck8m/rhabdomyosarcomaa


[ Back To TMCnet.com's Homepage ]